LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
ALPHARETTA, Ga., Aug. 08, 2017 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that it will participate in three upcoming events.
Clearside will host a Key Opinion Leader (“KOL”) luncheon event on Thursday, August 10, 2017 in Boston, MA. The invited speaker for this event is Dr. David M. Brown, a prominent Houston, TX-based retinal specialist and thought leader on the research and treatment of retinal vein occlusion (“RVO”), diabetic macular edema (“DME”) and age-related macular degeneration (“AMD”). The KOL lunch event will not be webcast.
Clearside’s Chief Executive Officer and President, Daniel H. White, will participate in a panel discussion on retinal drug delivery at the Ophthalmology Innovation Summit (“OIS”) to be held Thursday, August 10, 2017 in conjunction with the 35th Annual Scientific Meeting of the American Society of Retinal Specialists (“ASRS”) in Boston, MA. The panel discussion at OIS@ASRS will not be webcast.
Clearside management will also participate in the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017 at the Le Parker Meridien Hotel in New York, NY. Mr. White will participate in a lunch panel entitled, “New Technologies in Drug Delivery,” at 11:30 a.m. ET and will present at 2:30 p.m. ET. A live webcast of the presentation can be accessed on Clearside’s website at www.clearsidebio.com under the “Events & Presentations” tab in the “Investor Relations” section. Following the conference, the presentation webcast will be archived on the website for 30 days.
About Clearside
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and preclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, RVO, DME and AMD. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Contacts: Stephen Kilmer Investor Relations (678) 270-3631 [email protected] Charles Deignan Chief Financial Officer (678) 270-4005 [email protected]
